centerforbiosimilars1d
The Top 5 Biosimilar Articles for the Week of February 17
Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...
centerforbiosimilars2d
EC Approves Celltrion Denosumab, Aflibercept Biosimilars
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...
centerforbiosimilars2d
Josh Canavan, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2d
Adrian Goh, MEc
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3d
Alex Gerlach
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3d
Rosalind Wong, PharmD Candidate
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3d
Paul Cornes, BM, BCH, MA, MRCP, FRCR
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3d
Derek Burns, PharmD, MBA, BCPS, BCSCP
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3d
James D. Chambers, PhD, MPharm, MSc
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
Jeff Patton, MD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
John Bujnoski
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
Denise Myshko
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...